Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Six weeks of sofosbuvir/ledipasvir is enough to cure acute hepatitis C in HIV-negative people

A regimen of sofosbuvir/ledipasvir (Harvoni) taken for six weeks cured all patients with genotype 1 acute hepatitis C virus (HCV) infection, including those with high viral loads,

Published
18 April 2016
By
Liz Highleyman
Tenofovir alafenamide works well against hepatitis B with less effect on bones and kidneys

The new tenofovir alafenamide (TAF) pro-drug is as potent against hepatitis B virus (HBV) as the current tenofovir disoproxil fumarate (TDF) formulation, but with fewer detrimental effects

Published
18 April 2016
By
Liz Highleyman
Low-cost generic hepatitis C drugs match branded products in viral response

Generic versions of direct-acting antivirals purchased from China and India by people unable to obtain treatment in their own countries were just as effective and safe as

Published
16 April 2016
By
Keith Alcorn
Shifting hepatitis C treatment to primary care providers could expand availability

Hepatitis C treatment managed by non-specialists such as primary care physicians and nurse practitioners is as safe and effective as treatment delivered by specialists and could help

Published
15 April 2016
By
Liz Highleyman
Sofosbuvir/velpatasvir + GS-9857 works well for treatment-experienced hepatitis C patients

A triple combination of Gilead Sciences' sofosbuvir, velpatasvir and GS-9857 demonstrated a high sustained response rate for treatment-experienced people with all hepatitis C virus (HCV) genotypes who previously

Published
15 April 2016
By
Liz Highleyman
Hepatitis C treatment may not be enough to stop the progress of advanced liver disease, or reduce liver transplant need

Doctors need to have “full and frank” discussions with patients about the potential risks and benefits of using direct-acting antivirals (DAAs) to treat hepatitis C in late-stage

Published
14 April 2016
By
Keith Alcorn
Innovative new programme set to treat 10,000 patients co-infected with hepatitis C and HIV in Africa and Asia

The World Hepatitis Alliance welcomes the announcement of a new programme initiated by the Clinton Health Access Initiative, Inc. (CHAI) and AmeriCares that aims to treat 10,000 co-infected HIV and hepatitis C patients in Africa and Asia with new hepatitis C treatment Daklinza (daclatasvir).

Published
14 April 2016
From
World Hepatitis Alliance
Research shows doctors are failing to diagnose more than 50% of patients with hepatitis C virus (HCV)

Survey results show people living with HCV in the UK, the Netherlands and Belarus are less likely to be diagnosed than their global counterparts, increasing the possibility of liver disease, cirrhosis and liver cancer. Findings from HCV Quest, a global patient survey with 4,000 respondents from across the world, showed that half of people diagnosed with HCV reported that their doctors had initially failed to recognise symptoms and less than 46% were referred for a test.

Published
14 April 2016
From
World Hepatitis Alliance
Hepatitis C: The task now is identifying people who don’t know they’re infected and connecting them to care

Interview with Luis Mendão, chair of both the European AIDS Treatment Group (EATG) and Group of Activists on Treatments (GAT), a treatment activist group in Portugal.

Published
14 April 2016
From
BioMed Central blogs
Hepatitis C: Let’s not forget ‘prevention as prevention’

Interview with Eberhard Schatz, one of the two coordinators of Correlation, the European social inclusion and health network.

Published
14 April 2016
From
BioMed Central blogs

Filter by country